Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.55 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8224471 | 0.86 | SLC5A2 (0.55) | SLC5A2SLC5A1 | |
| SCHEMBL15981949 | 0.86 | ACHE (0.43) | SLC5A2 | |
| SCHEMBL15820966 | 0.86 | SLC5A2 (0.51) | SLC5A2 | |
| SCHEMBL15820964 | 0.86 | SLC5A2 (0.51) | SLC5A2 | |
| SCHEMBL15982081 | 0.85 | ACHE (0.42) | SLC5A2 | |
| SCHEMBL27730414 | 0.84 | TYR (0.55) | SLC5A2SLC5A1 | |
| SCHEMBL27709951 | 0.83 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL29197612 | 0.83 | SLC29A1 (0.40) | SLC5A2 | |
| SCHEMBL29197613 | 0.83 | SLC29A1 (0.40) | SLC5A2 | |
| SCHEMBL27709964 | 0.83 | SLC5A2 (0.49) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902157-B2 | Spirocyclic azetidin(one); e.g. 2,7-diazaspiro[3.5]nonan-1-one; T-type calcium channel blockers; Niemann-Pick C1-like (NPC1L1) antagonists | SCHERING CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080070890-A1 | Spirocyclic Azetidinone Compounds and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
| US-20080070889-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070890-A1 | Spirocyclic Azetidinone Compounds and Methods of Use Thereof | LIPC, ZDHHC20, PMP22 | SLC5A2 135/4885SLC5A1 175/4885 |
| US-20080070889-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | CYP46A1, OPRD1, OPRK1 | SLC5A2 1371/4885SLC5A1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.